Axonics is a company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

The Company plans to develop and clinically document superior performance of a miniaturized implantable neurostimulator platform targeting different indications. Axonics is planning to commercialize a spinal cord stimulation (SCS) device that is functionally comparable to current commercially available devices but smaller in size. In addition, the Company plans to document the system to treat chronic pain via peripheral nerve stimulation (PNS), in which an electrode array is placed directly on the nerve that innervates the painful area of the body.